GlassScriptPhysician profile
Daniel K Barnett
NPI 1952396673
$2,715.88
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,945 · 2020: $670 · 2021: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $242.95 | 2020-2021 | |
| Glaxosmithkline, LLC. | $218.58 | 2019-2020 | |
| Pfizer INC. | $214.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $199.99 | 2019 | |
| Lilly USA, LLC | $187.91 | 2019-2020 | |
| Amgen INC. | $163.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.62 | 2019-2020 | |
| Novo Nordisk INC | $147.89 | 2019 | |
| Amarin Pharma, INC. | $122.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $116.95 | 2019 | |
| Astellas Pharma US INC | $107.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2019 | |
| Angiodynamics, INC. | $83.33 | 2019 | |
| Merck Sharp & Dohme LLC | $76.68 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $69.87 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $68.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $61.49 | 2019-2020 | |
| Antares Pharma, INC. | $60.52 | 2019-2020 | |
| Allergan, INC. | $39.96 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.84 | 2019-2020 | |
| Sanofi Pasteur INC. | $25.24 | 2019 | |
| Circassia INC. | $19.84 | 2019 | |
| Radius Health, INC. | $19.63 | 2019 | |
| Eisai INC. | $19.01 | 2020 | |
| Aytu Biopharma, INC. | $17.95 | 2019 | |
| Mylan Specialty L.P. | $17.06 | 2020 | |
| Abbvie INC. | $13.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.03 | 2020 | |
| Abbott Laboratories | $10.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.